DANZIG RICHARD J 4
4 · HUMAN GENOME SCIENCES INC · Filed Aug 1, 2012
Insider Transaction Report
Form 4
DANZIG RICHARD J
Director
Transactions
- Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $11.33Exp: 2016-04-27→ Common Stock (16,000 underlying) - Disposition to Issuer
Common Stock
2012-07-30$14.25/sh−4,166$59,366→ 7,334 total - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $10.70Exp: 2017-05-03→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $14.23Exp: 2022-05-17→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $11.51Exp: 2015-05-26→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $5.97Exp: 2018-05-08→ Common Stock (16,000 underlying) - Disposition from Tender
Common Stock
2012-07-30$14.25/sh−7,334$104,510→ 0 total - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $2.09Exp: 2019-05-07→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−48,000$684,000→ 0 totalExercise: $10.69Exp: 2014-05-21→ Common Stock (48,000 underlying)
Footnotes (8)
- [F1]Each restricted stock unit represents a contingent right to receive one (1) share of Human Genome Sciences, Inc. common stock. These restricted stock units were cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $59,365.50, ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These restricted stock units vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $46,720.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $56,800.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $194,560.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $132,480.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $320.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $170,880.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F8]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $43,840.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.